Cystatin C Laboratory Testing
A laboratory request for cystatin C refers to a blood test that measures this protein to estimate kidney function (glomerular filtration rate/GFR), serving as an alternative or confirmatory marker to serum creatinine for diagnosing and staging chronic kidney disease (CKD).
What Cystatin C Measures
Cystatin C is a 13-kDa cysteine protease inhibitor produced at a constant rate by all nucleated cells in the body 1. Unlike creatinine, it is not significantly affected by:
- Muscle mass
- Age
- Sex
- Diet (including protein intake or vegetarian diets)
- Race 2
The protein is freely filtered by the glomeruli and serves as a biomarker for estimating GFR, which reflects how well the kidneys are filtering waste from the blood 3, 4.
Current Guideline Recommendations
The NKF-ASN Task Force (2022) recommends national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm eGFR in adults who are at risk for or have CKD 2. The guidelines specifically state that combining filtration markers (creatinine and cystatin C) is more accurate and supports better clinical decisions than either marker alone 2.
The 2024 KDIGO guidelines recommend using equations that integrate both serum creatinine and cystatin C for CKD diagnosis and staging 5.
Clinical Applications
Primary Uses:
- Confirmatory testing when creatinine-based eGFR suggests CKD stage 3a (eGFR 45-60 mL/min/1.73 m²) without proteinuria 2, 6
- Risk stratification for patients with mild to moderately reduced kidney function 7
- More accurate GFR estimation in populations where creatinine is unreliable 4:
- Patients with extremes of muscle mass (sarcopenia, cirrhosis, malnutrition, malignancies)
- Limb amputees
- Vegetarians
- Elderly patients
- Patients on medications affecting creatinine secretion (H2 blockers, trimethoprim, fenofibrate)
Prognostic Value:
Cystatin C demonstrates superior ability compared to creatinine alone to predict 1, 5:
- Kidney failure requiring replacement therapy
- Cardiovascular events
- Mortality risk
- Short-term mortality in patients with elevated cystatin C despite normal creatinine 3
How Results Are Used
The test generates estimated GFR values using validated equations 2:
- eGFRcys: Based on cystatin C alone
- eGFRcr-cys: Combined creatinine and cystatin C equation (most accurate)
- eGFRcr: Traditional creatinine-based equation
In clinical practice, approximately 47% of patients show discordance between creatinine-based and cystatin C-based eGFR estimates 3. The combined equation (eGFRcr-cys) mitigates this discordance and provides the most reliable assessment 3.
Important Clinical Context
When to Order:
- Confirming CKD diagnosis when creatinine-based eGFR is borderline
- Patients with conditions affecting muscle mass
- Risk stratification for adverse outcomes
- Medication dosing decisions requiring accurate GFR
- Cancer care and kidney transplantation monitoring 5
Current Limitations:
Despite strong evidence and guideline recommendations, cystatin C remains underutilized. A 2017 UK study found only 2.1% of laboratories offered the test, despite an estimated need for 2 million people requiring cystatin C testing for proper CKD staging 6. Recent data shows sustained utilization is increasing in health systems that have implemented it, with 76% of testing performed appropriately in patients with kidney disease 3.
Key Advantages Over Creatinine Alone
Cystatin C-based equations eliminate racial bias in GFR estimation 2. The race variable is not needed in cystatin C calculations, addressing health equity concerns with traditional creatinine-based equations that included race modifiers 2.
The test provides earlier detection of kidney dysfunction, particularly in hospitalized patients and those undergoing significant changes in muscle mass during weight loss or critical illness 5.